SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-24. Numbers and descriptions here follow the published literature rather than marketing material.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Armaan Kohli, Indian actor Bisham Kohli, Indian film personality, better known as Vishal Anand Girish Kohli (born 1983), Indian author and screenwriter Gurdeep Kohli (born 1980), Indian actor Hardeep Singh Kohli (born 1969), British presenter Himansh Kohli (born 1989), Indian actor Jas Kohli, Indian author Kuku Kohli (born 1949), Indian director, writer, editor and screenwriter Kunal Kohli (born 1969), Indian film director, producer and writer Narendra Kohli (1940–2021), Indian Hindi-language author Neelu Kohli, Indian television actress Nishi (actress) (born 1935), Indian actor Purab Kohli (born 1979), Indian actor, model and former video jockey Rahul Kohli, English actor Rajkumar Kohli (1930–2023), Indian film director Raul Kohli, English standup comedian Rochak Kohli (born 1983), Indian music director, composer, singer, instrumentalist and lyricist Sanjeev Kohli (born 1971), British Indian comedian, writer and actor Seema Kohli, Indian artist Sunita Kohli, Indian interior designer Vikas Kohli, Indian musician and music producer
==== Mycotoxins ==== In April 2014, aflatoxin B1, a known carcinogenic toxin, melamine, and cyanuric acid were all found in various brands of USA pet food imported into Hong Kong. Since 1993, the FDA has confirmed concerns of toxins in feed grade (animal grade) ingredients, yet to date no comprehensive federal regulation exists on mycotoxin testing in feed grade (animal grade) ingredients used to make pet food. In 1997, the Journal of Food Additives and Contaminants established that low levels of various mycotoxins could cause health concerns in pets, and was found in feed grade ingredients. A study published in the Journal of Food Protection in 2001 cited concerns regarding fungi (the source of mycotoxins) in commercial pet foods and warned about the "risk for animal health". In 2006, a study published in the Journal of Agricultural and Food Chemistry confirmed mycotoxins in pet foods around the world and concluded that contamination of mycotoxins in pet foods can lead to chronic effects on the health of pets. In 2007, the International Journal of Food Microbiology published a study that claimed "mycotoxin contamination in pet food poses a serious health threat to pets", and listed them: aflatoxins, ochratoxins, trichothecenes, zearalenone, fumonisins and fusaric acid. A 2008 study published in the Journal of Animal Physiology and Animal Nutrition found high levels of mycotoxins in the raw ingredients used for pet food in Brazil. A 2010 study in the Journal of Mycotoxin Research tested 26 commercial dog foods and found mycotoxins at concerning sub-lethal levels.
== References == Atmore, Anthony; Sanders, Peter (1971). "Sotho Arms and Ammunition in the Nineteenth Century". The Journal of African History. 12 (4): 535–544. doi:10.1017/S0021853700011130. ISSN 0021-8537. JSTOR 181011. S2CID 161528484. Bradlow, Edna (1970). "General Gordon in Basutoland". Historia. 15 (4): 223–242. ISSN 0018-229X. Retrieved 7 November 2021. Burman, Sandra (1981). Chiefdom Politics and Alien Law: Basutoland under Cape Rule 1871–1884. Palgrave Macmillan. ISBN 978-1-349-04639-3. Eldredge, Elizabeth (2007). Power in Colonial Africa: Conflict and Discourse in Lesotho, 1870–1960. The University of Wisconsin Press. ISBN 978-0-299-22370-0. Kotze, J. (2012). "Counter-Insurgency in the Cape Colony, 1872–1882". Scientia Militaria: South African Journal of Military Studies. 31 (2): 36–58. doi:10.5787/31-2-152. Retrieved 7 November 2021. Machobane, L. B.; Karschay, Stephan (1990). Government and Change in Lesotho, 1800–1966: A Study of Political Institutions. Palgrave Macmillan. ISBN 978-0-333-51570-9. Maliehe, Sean (2014). "An obscured narrative in the political economy of colonial commerce in Lesotho, 1870–1966". Historia. 59 (2): 28–45. hdl:2263/43121. ISSN 0018-229X. Retrieved 7 November 2021. Rosenberg, Scott; Weisfelder, Richard; Frisbie-Fulton, Michelle (2004). Historical Dictionary of Lesotho. The Scarecrow Press. ISBN 0-8108-4871-6. Tylden, G. (1936). "The Basutoland Rebellion of 1880–1881". Journal of the Society for Army Historical Research. 15 (58): 98–107. ISSN 0037-9700. JSTOR 44227993.
second messenger Also secondary messenger. A molecule or compound (often a protein) that is caused to accumulate in an effector cell by the action of a hormone, growth factor, or other agonist and thereby brings about the action of that agonist on the cell. Second messengers are therefore critical mediators of a diverse variety of signal transduction pathways, including the synthesis of cyclic AMP by adenylate cyclase and of cyclic GMP by guanylate cyclase, the opening of ion channels, and the phosphorylation of proteins by serine/threonine-specific or tyrosine-specific protein kinases.
These formulas are only approximate, especially for small n and m where the bonds are strained, and they do not take into account the thickness of the wall. The tilt angle α between u and w and the circumference c are related to the type indices n and m by:
Sources: en.wikipedia.org
=== 18 June === Ukrainian forces retook the village of Tykhe, west of Vovchansk. In Russia, the governor of Rostov Oblast claimed that several oil storage tanks were set on fire by a drone strike in Azov that destroyed 5,000 cubic metres of petroleum products. An oil depot in Krasnodar Krai was struck by Neptune missiles according to local sources, damaging a pipeline, “technical facilities” and starting a fire. No casualties were reported. A Ukrainian court sentenced a resident of Donetsk Oblast to 15 years' imprisonment for spying on Ukrainian positions on behalf of Russia during the Battle of Bakhmut. Swiss authorities claimed to have foiled an assassination attempt aimed at the Ukrainian peace summit, saying that a Russian diplomat was arrested a “few weeks” prior after trying to buy firearms. Ukrainian military observer Kostyantyn Mashovets claimed that the Russian Central Grouping of Forces has about 87,000 personnel, 365 tanks, 864 armored combat vehicles, of which about 68,000-70,000 personnel, 310-320 tanks, and about 576 armored fighting vehicles are currently deployed in the Pokrovsk direction.
==== RNA sequencing (RNA-seq) ==== Whole transcriptome shotgun sequencing (WTSS) is the latest in gene expression studies, using next generation sequencing (NGS) to quantify RNA in samples on a high throughput scale. As biology trends toward using RNA-seq over microarray analysis in evaluating the transcriptome, so does degradomics. The field adapts the approach to analyzing the presence and quantity of transcripts of proteases, their substrates, and their inhibitors. While developed microarrays remain a major workhorse in studying gene expression in degradomics, its limitations of cross hybridization and dynamic range issues suggest RNA-seq will take a larger role as costs decrease and analysis improves.
== The influence of age: age-structured models == Age has a deep influence on the disease spread rate in a population, especially the contact rate. This rate summarizes the effectiveness of contacts between susceptible and infectious subjects. Taking into account the ages of the epidemic classes
=== Quantitative sudomotor axon reflex test === The quantitative sudomotor axon reflex test (QSART) was developed in 1983 by Phillip Low as a quantitative method for the identification of localized postganglionic sudomotor dysfunction. Three-compartment sweat capsules are placed on the forearm, proximal and distal leg, as well as the dorsum of the foot. The outer compartment of the capsule is filled with a 10% acetylcholine solution, while nitrogen gas is released steadily onto the skin within the inner compartment. The middle compartment acts as a buffer between the inner and outer compartments to prevent direct stimulation of sweat glands or leakage of the acetylcholine solution. The outflow humidity of the nitrogen gas after passing across the skin is measured by a hygrometer. Once a stable baseline of outflow humidity is reached, iontophoresis of the acetylcholine fluid is initiated by using a 2mA electric current to deliver the acetylcholine into the dermal skin layers. The acetylcholine binds to sweat glands (direct sweat response), and nicotinic and muscarinic receptors on the sudomotor nerve terminals, which transmit the action potential antidromically to axon branch points and then orthodromically to adjacent sudomotor nerves and glands (indirect sweat response). Sweat production is measured as the change in relative humidity over time. The temporal resolution, magnitude, and onset latency of the sweat response are digitally recorded and analyzed using specialized software. QSART is sensitive and specific for detecting postganglionic small fiber dysfunction.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.